Healthy Clinical Trial
— AMPOfficial title:
The Effects of Blueberry Anthocyanin Metabolism on Acute Cardiometabolic Health
Verified date | January 2021 |
Source | University of East Anglia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to find out if consuming a single dose of blueberries, rich in anthocyanins, within an energy dense meal, improves blood vessel function and biomarkers of heart health. The study specifically aims to confirm if differences in how individuals process the bioactive compounds in blueberries, called anthocyanins, has an influence on heart health. The investigators will assess the effects of eating one portion of blueberries on vascular health over a 48hour period, and will track the breakdown compounds within blood and urine, to see if health effects are related to metabolism.
Status | Terminated |
Enrollment | 49 |
Est. completion date | January 6, 2021 |
Est. primary completion date | January 6, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion Criteria: - BMI >= 25 kg/m2 - Adults aged 50 - 80 years old - Successful biochemical, haematological, and urinalysis assessment at screening Exclusion Criteria: - Current smokers, or ex-smokers ceasing < 6 months ago - existing or significant past medical history of vascular disease or medical conditions likely to affect the study measures - Fructose or lactose intolerant subjects or known allergies to intervention treatments - Those unprepared to adhere to dietary instructions - Parallel participation in another research project involving dietary intervention and/or sampling of biological fluids/material - Those on therapeutic diets or having experienced substantial weight loss within 2 months of screening. - Those taking flavonoid, nitrate / nitrite containing or fish oil containing supplements (and unwilling to cease intake during, and 1 month preceding the trial) or unwilling to maintain existing intake of other supplements. - Prescribed hypoglycaemic, anti-hypertensive, vasodilator or hormone replacement therapy (HRT) medication. - Unsatisfactory biochemical, haematological or urinary results or measurements considered to be counter indicative for the study - Undiagnosed hypertension (elicited at screening; i.e. = 180 / 110mmHg) at a level requiring immediate referral back to general practitioner for follow-up |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Quadram Institute Clinical Research Facility; a partnership facility of the NHS, UEA and QIB | Norwich | Norfolk |
Lead Sponsor | Collaborator |
---|---|
University of East Anglia |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Microbiome assessment of phyla and species | Assessment of the gut microbiome from faecal samples collected from FAST and SLOW anthocyanin metabolisers. | Sample collected up to 2 days prior to test meal 1 and assessed within 5 years of study completion | |
Other | Ambulatory blood pressure | Measurement of pre-intervention and postprandial ambulatory blood pressure | 1 day before, and the two days following the intake of each energy dense test meal | |
Other | Aortic arterial stiffness (cf-PWV) | Measurement of carotid to femoral pulse wave velocity | assessed at 0, 3, 6, 24, 48 hours after intervention intake | |
Other | Systemic arterial stiffness (AIx) | Measurement of brachial augmentation index (adjusted to 75 beats per minute heart rate) | assessed at 0, 3, 6, 24, 48 hours after intervention intake | |
Other | Bioavailability - urine | Assessment of flavonoid and metabolite levels in 24 hour urine samples | 3 days during the blueberry challenge (1 day before and the two days of the assessment) and 3 days during each test meal assessment (1 day before and the two days of the assessment) | |
Other | Postprandial glucose response | Assessment of postprandial glucsoe control | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. | |
Other | High density lipoprotein cholesterol | Assessment of blood high density lipoprotein cholesterol | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. | |
Other | Triglycerides | Assessment of blood triglycerides | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. | |
Other | Low density lipoprotein cholesterol | Assessment of blood low density lipoprotein cholesterol | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. | |
Primary | Brachial artery endothelial function | percentage maximum dilatation assessed via flow mediated dilation (%FMD): (diametermax-diameterbaseline) / diameterbaseline×100. | assessed at 0, 1.5, 3, 6, 24, 48 hours after intervention intake | |
Secondary | Office blood pressure | Measurements of blood pressure | Assessed at 0, 3, 6, 24, 48 hours after intervention intake. | |
Secondary | Bioavailability - serum | Assessment of flavonoid and metabolite levels in blood samples | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. | |
Secondary | Postprandial Insulin response | Assessment of postprandial insulin control | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. | |
Secondary | Total cholesterol | Assessment of blood cholesterol | Measured prior to, and then at +20, +40, +60, +90, +120, +180, +270 and +360 minutes, +24 hours and +48 hours following the energy dense meal intake. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |